# US 2013/0252906 A1 · Compounds and methods for treating or preventing disease conditions associated with alpha-1-antitrypsin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252906 A1
- Document ID: US20130252906A1
- Status: Published application
- Kind: A1
- Application number: 13/879,160
- Filed: 2011-10-14
- Published: 2013-09-26
- Earliest claimed: 2010-10-14
- Assignees: Amicus Therapeutics, Inc.
- Inventors: Eric Richard Sjoberg; Gary Lee
- Web page: https://patentgrep.com/patent/US20130252906A1

## CPC

- A61K 38/07: Tetrapeptides
- C07C 231/06: from nitriles by transformation of cyano groups into carboxamide groups
- C07C 281/06: Compounds containing any of the groups [IMAGE cpc-sch-C07C-0973.gif], e.g. semicarbazides
- C07K 5/1013: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 7/06: having 5 to 11 amino acids
- C12Q 1/37: involving peptidase or proteinase
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/8125: Alpha-1-antitrypsin
- G01N 2333/966: Elastase
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Pharmacological chaperone compounds and methods for the treatment of an individual having, or at risk of having, a disease condition associated with alpha-1-antitrypsin by using said compounds are disclosed. In particular, such methods are useful for the treatment or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. Also provided is an assay for determining whether a test compound modulates alpha-1-antitrypsin activity.

## Claims

### Claim 1

A method of treating an individual having or at risk of having a disease condition associated with α-1-antitrypsin comprising administering to the individual an effective amount of a pharmacological chaperone.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmacological chaperone is:
wherein:
R1 is —(CH2)2—COOH or —CH2—OH
R2 is —CH3 or —CH—(CH3)2,
wherein:
R3 is —H or —CH3
R4 is —H or —OCH3
R5 is —H or —OH,
or combinations of two or more thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmacological chaperone is:
Ac-Thr-Glu-Ala-Ala-NH2,
Ac-Thr-Glu-Ala-Ala-Gly-NH2,
Ac-Thr-Ser-Ala-Ala-NH2,
Ac-Thr-Glu-Val-Ala-NH2 or combinations of two or more thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmacological chaperone is Ac-Thr-Glu-Val-Ala-NH2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the individual has or is at risk of having one or more disease conditions associated with α-1-antitrypsin selected from cirrhosis, chronic obstructive pulmonary disease, pneumothorax, asthma, Wegener's granulomatosis, pancreatitis, gallstones, bronchiectasis, pelvic organ prolapse, primary sclerosing cholangitis, autoimmune hepatitis, emphysema and cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the individual has or is at risk of having a liver disorder associated with alpha-1-antitrypsin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the individual has or is at risk of having a lung disorder associated with alpha-1-antitrypsin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the individual has an E342 missense mutation in α-1-antitrypsin in at least one allele.

### Claim 9

A method for determining modulation of alpha-1-antitrypsin activity by a test compound comprising:
(a) providing a labeled elastin wherein cleavage of the labeled elastin by elastase results in a detectable signal;
(b) combining the test compound, the labeled elastin, elastase and alpha-1-antitrypsin; and
(c) measuring the detectable signal wherein a decrease in the detectable signal relative to that without the test compound indicates the test compound inhibits alpha-1-antitrypsin activity and an increase in the detectable signal relative to that without the test compound indicates the test compound enhances alpha-1-antitrypsin activity.

### Claim 10

A compound according to the structure:
wherein:
R1 is —(CH2)2—COOH or —CH2—OH
R2 is —CH3 or —CH—(CH3)2.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R1 is —CH2—OH and R2 is —CH3.

### Claim 12 (depends on 10)

The compound of claim 10, wherein R1 is —(CH2)2—COOH and R2 is —CH—(CH3)2.

### Claim 13 (depends on 10)

The compound of claim 10, wherein R1 is —(CH2)2—COOH and R2 is —CH3.

### Claim 14

A compound according to the structure:
wherein
R3 is —H or —CH3
R4 is —H or —OCH3
R5 is —H or —OH.

### Claim 15 (depends on 14)

The compound of claim 14 having the structure:

### Claim 16 (depends on 14)

The compound of claim 14 having the structure:

### Claim 17 (depends on 14)

The compound of claim 14 having the structure:

### Claim 18 (depends on 14)

The compound of claim 14 having the structure:

### Claim 19 (depends on 14)

The compound of claim 14 having the structure:

### Claim 20 (depends on 14)

The compound of claim 14 having the structure:
